- Neutra (OTCPK:NTRR) said on Friday it had paused its previously announced acquisition of Mercury Clinical Research.
- NTRR added it had put the transaction on hold “due to some internal housekeeping that Neutra must resolve before moving forward.”
- The company said it plans to reopen the deal once the “internal issues” have been resolved through a renewed letter of intent.
- In the interim, Mercury has contracted NTRR services via the “Clinical Foundations” service model, the company added.
- NTRR added it had decided to merge VIVIS and Deity Wellness into one brand.
- Press Release
Trending
- ‘I want to die “young” as late as possible,’ says 83-year-old triathlete doctor who reinvented himself after a midlife crisis
- 10 Israeli Soldiers Hospitalized After Wasp Swarm Attack
- Construction Partners posts strong Q2 amid high demand By Investing.com
- ZIM Integrated sails to top industrial gainer of week, Builders FirstSource sees loser tag
- US Marine Says 40% of Drones the IDF Has Shot Down Were Their Own
- Amprius Technologies doubles customer base, boosts revenue By Investing.com
- My 19-year-old son wants to get married so Uncle Sam will ‘kick in more scratch’ for his girlfriend’s financial aid. Is this a terrible idea?
- Meet the Doomsayers Waiting for the Economy to Crash
Sunday, July 27
Neutra pauses Mercury Clinical Research acquisition (OTCMKTS:NTRR)
By 
